The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial

By sjmartinez • April 27, 2025

Golub LS, Manubolu VS, Aldana-Bitar J, Dahal S, Verghese D, Alalawi L, Krishnan S, Kianoush S, Benzing T, Ichikawa K, Kinninger A, Fazlalizadeh H, Pourafkari L, Ahmad K, Susarla S, Mangaoang C, Ghanem AK, Javier DA, Hamal S, Roy SK, Budoff MJ. The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial. Nutr Metab Cardiovasc Dis. 2025 Apr 5:104036. doi: 10.1016/j.numecd.2025.104036. Epub ahead of print. PMID: 40287313.

Tags: ASCVD, atherosclerotic cardiovascular disease, CAC, Cardiology/Epi, cardiovascular disease, Computed Tomography Angiography, coronary artery calcium, CTA, CVD, General Internal Medicine, GLP1 receptor agonists, Harbor UCLA, HCC, Hepatocellular carcinoma, MASH, MASLD, Metabolic dysfunction-associated Steatohepatitis, Metabolic dysfunction-associated steatotic liver disease, Publications, randomized trial, Resident, semaglutide

A deep learning phenome wide association study of the electrocardiogram

Hughes JW, Theurer J, Vukadinovic M, Rogers AJ, Somani S, Kang G, Ghazizadeh Z, O'Sullivan JW, Jain SS, Gomes B, Salerno M, Ashley E, Zou[...]

Novel insights into post-myocardial infarction cardiac remodeling through algorithmic detection of cell-type composition shifts

Gural B, Kirkland L, Hockett A, Sandroni P, Zhang J, Rosa-Garrido M, Swift SK, Chapski DJ, Flinn MA, O'Meara CC, Vondriska TM, Patterson M, Jensen[...]

The accumulation of progerin underlies the loss of aortic smooth muscle cells in Hutchinson-Gilford progeria syndrome

Kim PH, Kim JR, Heizer PJ, Jung H, Tu Y, Presnell A, Scheithauer J, Yu RG, Young SG, Fong LG. The accumulation of progerin underlies[...]